Trials / Completed
CompletedNCT03577652
The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 108 (actual)
- Sponsor
- Shenyang Northern Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is to further exploring the optimal switching strategy by evaluating the pharmacodynamic responses as well as adverse events in patients with complexity of coronary artery disease managed by percutaneous coronary intervention (PCI). All participants will be divided into three groups and recieving ticagrelor 90mg plus aspirin 100mg at 12 hours after the last dose of clopidogrel; recieving ticagrelor 90mg plus aspirin 100mg at 24 hours after the last dose of clopidogrel; recieving ticagrelor 180mg plus aspirin 100mg at 24 hours after the last dose of clopidogrel.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ticagrelor | Ticagrelor, 90mg, 90mg twice daily |
Timeline
- Start date
- 2017-07-10
- Primary completion
- 2018-01-10
- Completion
- 2018-01-10
- First posted
- 2018-07-05
- Last updated
- 2018-07-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03577652. Inclusion in this directory is not an endorsement.